Please Wait...

Serum Amyloid A (SAA)

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

SAA is an acute phase protein, mainly produced by the liver and released in response to inflammation or infections. Indeed, SAA production is stimulated by pro-inflammatory cytokines such as IL-6, IL-1 and TNF-α (Calabrò et al., 2010). SAA has a role in cholesterol metabolism as it circulates in low levels bound to High-Density Lipoprotein (HDL) (Coetzee et al., 1986). During inflammation, SAA levels strongly increase and the protein can constitute up to 80% of HDL apolipoproteins. SAA is also a precursor of amyloid A protein, an insoluble product whose pathological accumulation is named amyloidosis (Husebekk et al., 1985). Blood levels of SAA are increased in numerous inflammatory disorders including Rheumatoid Arthritis (Targonska-Stepniak and Majdan, 2014) .

Bioclinica Lab employs a manual sandwich immunoassay for the measurement of human SAA in serum.

Calabrò, P., Riegler, L., Limongelli, G., Maddaloni, V., Martone, F., Golia, E., D’Alessandro, R., Pacileo, G., Russo, M.G., Golino, P., et al. (2010). Production of Serum Amyloid a in Response to Inflammatory Cytokines by Human Adipocytes. Eur. J. Inflamm. 8, 99–105.

Coetzee, G.A., Strachan, A.F., van der Westhuyzen, D.R., Hoppe, H.C., Jeenah, M.S., and de Beer, F.C. (1986). Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261, 9644–9651.

Husebekk, A., Skogen, B., Husby, G., and Marhaug, G. (1985). Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand. J. Immunol. 21, 283–287.

Targonska-Stepniak, B., and Majdan, M. (2014). Serum Amyloid A as a Marker of Persistent Inflammation and an Indicator of Cardiovascular and Renal Involvement in Patients with Rheumatoid Arthritis. Mediators Inflamm. 2014, e793628.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @bioclinica: @CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of #MobileTechnologies in #CV…
bioclinica (5 minutes ago)
@CardiacSafety Consortium needs your feedback! Help make the upcoming think tank "Evaluation of… https://t.co/0Oc3z6zkO8
bioclinica (10 minutes ago)
RT @CDISC: Special thanks to CDISC Member @bioclinica for hosting CDISC Public Training in Audubon, PA 2-6 Apr 2018. Register today. https:…
bioclinica (26 minutes ago)
Bioclinica Delivers Individual Case Safety Report (ICSR) Processing w Quality & Consistency While Crossing One Mil… https://t.co/77NOME2Dj7
bioclinica (Yesterday)
Who made the BioSpace list of 11 most innovative life sciences companies in the world? Ck it out here via @biospace… https://t.co/f9vtRpsbMW
bioclinica (Yesterday)
BREAKING: With a passion for Drug Safety, we’re delighted to share @bioclinica #pharmacovigilance crossed 1M ICSR c… https://t.co/PAdROjo7tE
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen